-0.0061  (-0.87%)
Volume (24h): 2.52M Day Range: 0.6530 - 0.7399
Market Cap: 35.85M 52W Range: 0.2770 - 3.87
Mar-24-20 09:15PM Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational HighlightsGlobeNewswire
Mar-23-20 08:30PM Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor SummitGlobeNewswire
Mar-16-20 02:42PM 8 Biotechs With Coronavirus Vaccines In DevelopmentBenzinga
Mar-03-20 10:00PM Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct OfferingGlobeNewswire
Feb-28-20 01:45PM Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-MarketGlobeNewswire
Feb-27-20 02:21PM Southern Research collaborating to develop coronavirus vaccineAmerican City Business Journals
Feb-26-20 02:36PM The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 UpdatesBenzinga
12:00PM Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)GlobeNewswire
Feb-11-20 09:01PM Tonix Pharmaceuticals Announces Closing of $7.5 million Public OfferingGlobeNewswire
Feb-07-20 01:45PM Tonix Pharmaceuticals Prices $7.5 million Public OfferingGlobeNewswire
12:32PM The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO ResignsBenzinga
Feb-06-20 12:47PM The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOsBenzinga
Feb-05-20 10:15PM Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSDGlobeNewswire
Feb-04-20 12:00PM Tonix Pharmaceuticals to Participate in Upcoming February Investor ConferencesGlobeNewswire
Jan-30-20 02:26PM The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak GuidanceBenzinga
Jan-29-20 09:15PM Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats ConferenceGlobeNewswire
06:04PM Does The Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Share Price Tend To Follow The Market?Simply Wall St.
Jan-27-20 02:51PM Company News for Jan 27, 2020Zacks
Jan-24-20 12:00PM Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SLGlobeNewswire
Jan-23-20 12:00PM Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats ConferenceGlobeNewswire
Jan-07-20 12:00PM Tonix Pharmaceuticals to Present at Biotech Showcase 2020GlobeNewswire
Dec-16-19 08:15PM Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic StudyGlobeNewswire
12:20PM TNXP: TNX-102 SL P3 PTSD Trial Interim Readout in 1Q20; P3 Trial in Fibromyalgia Underway…Zacks Small Cap Research
Dec-13-19 02:23PM Company News for Dec 13, 2019Zacks
Dec-11-19 09:05PM Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SLGlobeNewswire
Dec-10-19 12:00PM Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewswire
Dec-04-19 12:00PM Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main EventGlobeNewswire
Dec-03-19 12:00PM Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price RequirementGlobeNewswire
Nov-26-19 09:05PM Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSDGlobeNewswire
Nov-25-19 09:05PM Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 ConferenceGlobeNewswire
Nov-22-19 01:18PM The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings EstimateBenzinga
Nov-21-19 02:40PM Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder DrugBenzinga
01:00PM Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewswire
Nov-21-19 12:22PM The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At NeonBenzinga
Nov-20-19 09:05PM Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use DisorderGlobeNewswire
12:00PM Tonix Pharmaceuticals Announces Closing of $9.0 Million Public OfferingGlobeNewswire
Nov-15-19 01:30PM Tonix Pharmaceuticals Prices $9.0 Million Public OfferingGlobeNewswire
Nov-08-19 09:45PM Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational HighlightsGlobeNewswire
Nov-04-19 12:00PM Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA MeetingGlobeNewswire
Oct-31-19 05:00PM Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock SplitGlobeNewswire
Oct-30-19 07:49PM Companies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Can Be Considered Quite RiskySimply Wall St.
Oct-23-19 11:54AM The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer DataBenzinga
11:00AM Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601GlobeNewswire
Oct-15-19 11:00AM Tonix Pharmaceuticals Joins the Alliance for BiosecurityGlobeNewswire
Oct-07-19 11:00AM Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSDGlobeNewswire
Oct-03-19 12:00PM Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mgGlobeNewswire
Sep-19-19 01:30PM TNXP: TNX-102 SL P3 PTSD Trial Enrolling; Pipeline Expansion Adds Phase 2 Program and Two Pre-Clinical Programs…Zacks Small Cap Research
Sep-17-19 11:23AM The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage StudyBenzinga
Sep-16-19 08:15PM Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic CancersGlobeNewswire
11:00AM Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of PharmacologyGlobeNewswire
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)